La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Coloplast Gestione

Gestione criteri di controllo 4/4

Coloplast's Il CEO è Kristian Villumsen, nominato in Dec2018, e ha un mandato di 5.67 anni. la retribuzione annua totale è DKK 23.30M, composta da 51.5% di stipendio e 48.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.045% delle azioni della società, per un valore di € 12.22M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.3 anni e 6.6 anni.

Informazioni chiave

Kristian Villumsen

Amministratore delegato

DKK 23.3m

Compenso totale

Percentuale dello stipendio del CEO	51.5%
Mandato del CEO	5.8yrs
Proprietà del CEO	0.05%
Durata media del management	6.5yrs
Durata media del Consiglio di amministrazione	6.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Kristian Villumsen rispetto agli utili di Coloplast?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	DKK 5b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	n/a	n/a	DKK 5b
Sep 30 2023	DKK 23m	DKK 12m	DKK 5b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	n/a	n/a	DKK 5b
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b

Compensazione vs Mercato: La retribuzione totale di Kristian ($USD 3.48M ) è inferiore alla media delle aziende di dimensioni simili nel mercato German ($USD 5.49M ).

Compensazione vs guadagni: La retribuzione di Kristian è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Kristian Villumsen (54 yo)

5.8yrs

Mandato

DKK 23,300,000

Compensazione

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kristian Villumsen	President & CEO	5.8yrs	DKK 23.30m	0.045% € 12.2m
Anders Lonning-Skovgaard	Executive VP & CFO	10.3yrs	DKK 11.90m	0.0012% € 318.9k
Allan Rasmussen	Executive Vice President of Global Operations	10.3yrs	DKK 10.50m	0.011% € 3.1m
Nicolai Andersen	Executive Vice President of Innovation	no data	DKK 10.00m	Nessun dato
Paul Marcun	Executive Vice President of Growth	5.8yrs	DKK 12.00m	0.014% € 3.7m
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000020% € 5.4k
Ellen Bjurgert	Vice President of Investor Relations	8yrs	Nessun dato	Nessun dato
Dennis Kaysen	Director of Corporate Communications	no data	Nessun dato	Nessun dato
Dorthe Ronnau	Senior Vice President of People & Culture	2.8yrs	Nessun dato	Nessun dato
Alain Morvan	Senior Vice President of Sales Europe	12.5yrs	Nessun dato	Nessun dato
Rasmus Møller	Senior Vice President of Wound & Skin Care	4.1yrs	Nessun dato	Nessun dato
Manu Varma	Senior Vice President of Chronic Care - North America	6.5yrs	Nessun dato	Nessun dato

6.5yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di CBHD è esperto e expertise (durata media dell'incarico 6.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Barfod	Senior Controller & Employees Representative Director	18.8yrs	DKK 450.00k	0.000020% € 5.4k
Carsten Hellmann	Independent Director	6.8yrs	DKK 690.00k	0.0027% € 721.5k
Lars Rasmussen	Chairman of the Board	5.8yrs	DKK 1.84m	0.0054% € 1.5m
Niels Louis-Hansen	Deputy Chairman	56.8yrs	DKK 938.00k	1.93% € 521.0m
Marianne Wiinholt	Independent Director	3.8yrs	DKK 880.00k	0.00022% € 59.5k
Jette Nygaard-Andersen	Independent Director	8.8yrs	DKK 600.00k	Nessun dato
Nikolaj Gundersen	Employees Representative Director	6.8yrs	DKK 450.00k	Nessun dato
Roland Pedersen	Employees Representative Director	6.8yrs	DKK 450.00k	0.00072% € 194.6k
Annette Bruls	Independent Director	2.8yrs	DKK 600.00k	Nessun dato

6.8yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CBHD sono considerati esperti (durata media dell'incarico 6.6 anni).

Coloplast Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Deputy Chairman recently bought €5.4m worth of stock

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Recent updates

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Third quarter 2024 earnings released: EPS: kr.5.67 (vs kr.5.99 in 3Q 2023)

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

First half dividend of kr.5.00 announced

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

New major risk - Financial position

Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023)

First quarter 2024 earnings released

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 21% undervalued after recent price drop

Full year 2023 earnings released

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought €5.4m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022)

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Upcoming dividend of kr.15.00 per share

Less than half of directors are independent

Coloplast Announces Executive Changes

Full year 2022 earnings released: EPS: kr.22.17 (vs kr.22.67 in FY 2021)

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Third quarter 2022 earnings released

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

New 90-day low: €117

First quarter 2021 earnings released

Revenue beats expectations

New 90-day high: €136

New 90-day low: €119

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

New 90-day low: €122

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

New 90-day low: €128

New 90-day low: €130

New 90-day low - €132

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

New 90-day low - €137

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato